While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

No longer a mere assistant who carries out the commands of DNA, RNA takes the lead in emerging therapeutics.

Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Industry Trends Published: September 1999 Cardiovascular disease drug discovery Aris Persidis Nature Biotechnology 17, 930–931 (1999) Cite this article ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

While rarely explicitly taught to scientists in training, a set of common values guides science in the quest to advance ...

A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts ...

UB scientists Ram Samudrala, PhD, and Zackary M. Falls, PhD, talk about the new platform to make drug discovery faster and less expensive while also being safe and effective.

The comic duo’s High & Dry THC-infused seltzers mark a groundbreaking moment in the spirits industry as the first-ever cannabis beverage to sponsor the revered Spirited Awards NEW ORLEANS, LA / ACCESS ...

A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.